Citi Pharma Maintains Steady Profit in 1QFY26 Despite Rising Financial Costs
Citi Pharma Limited posted a profit after tax of Rs203.69 million for 1QFY26, marking a 1% rise from last year. While higher finance costs and reduced other income pressured margins, improved gross profit and lower taxation helped sustain steady earnings.
Citi Pharma Issues Clarification on Iraq Expansion Rumors to Counter Misinformation
Citi Pharma has officially denied reports about its alleged Iraq expansion plans, clarifying that no agreements or commitments have been made and urging media platforms to remove inaccurate information.